

Topical Scientific Workshop on Regulatory Challenges in Risk Assessment of Nanomaterials October 23-24, 2014 Helsinki, Finland

<u>Topic 3</u>: Metrology and dose metrics for hazard and exposure assessment throughout the life cycle

Concepts of Nanoparticle Toxicology, Dosimetry and Risk Assessment

> Günter Oberdörster University of Rochester, NY




Concepts to be addressed:

— Key parameters of nanomaterials affecting hazard properties as basis for testing and for using metrics

— Mode of action and choice of dosemetrics


— Approach involving dosimetry and dosemetrics for regulatory hazard and risk characterization

Nanotoxicology - Hype Cycle




Effects and Biokinetics of UFP (1990s)

Conceptual Depiction of Factors for Considering Dose-dependent Transitions in Determinants of Toxicity



From: Slikker Jr., et al. 2004

Toxicology 254 (2008) 82-90



Jiangxue Wang^{a,b}, Ying Liu^{a,b}, Fang Jiao^{a,b}, Fang Lao^{a,b}, Wei Li^{a,b}, Yiqun Gu^c, Yufeng Li^{a,b}, Cuicui Ge^{a,b}, Guoqiang Zhou^{a,b}, Bai Li^{a,b}, Yuliang Zhao^{a,b,*}, Zhifang Chai^{a,b}, Chunying Chen^{a,b,**}

³ Laboratory for Bio-Environmental Effects of Nanomaterials and Nanosafety and Key Lab of Nuclear Analytical Techniques Institute of High Energy Diverses. Chinese Acai ^b National Ci ^c Maternity J

Nanoparticles can be administered via nasal, oral, intraocular, intratracheal (pulmonary toxicity), tail vein and other routes. Here, we focus on the time-dependent translocation and potential damage of TiO₂ nanoparticles on central nervous system (CNS) through intranasal instillation. Size and structural properties are important to assess biological effects of TiO₂ nanoparticles. In present study, female mice were intranasally instilled with two types of well-characterized TiO₂ nanoparticles (i.e. 80 nm, rutile and 155 nm, anatase; purity > 99%) every other day. Pure water instilled mice were served as controls. The brain tissues were collected and evaluated for accumulation and distribution of TiO₂, histopathology, oxidative stress, and inflammatory markers at post-instillation time points of 2, 10, 20 and 30 days. The titanium contents in the sub-brain regions including olfactory bulb, cerebral cortex, hippocampus, and cerebellum were determined by inductively coupled plasma mass spectrometry (ICP-MS). Results indicated that the instilled TiO₂ directly entered the brain through olfactory bulb in the whole exposure period, especially deposited in the hippocampus region. After exposure for 30 days, the pathological changes were observed in the hippocampus and olfactory bulb using Nissl staining and transmission electron microscope. The oxidative damage expressed as lipid peroxidation increased significantly, in particular in the exposed group of anatase TiO₂ particles at 30 days postexposure. Exposure to anatase TiO₂ particles also produced

Toxicology 254 (2008) 82-90



^b National C ^c Maternity


Nanoparticles can be administered via nasal, oral, intraocular, intratracheal (pulmonary toxicity), tail vein and other routes. Here, we focus on the time-dependent translocation and potential damage of TiO₂ nanoparticles on central nervous system (CNS) through <u>intranasal instillation</u>. Size and structural properties are important to assess biological effects of TiO₂ nanoparticles. In present study, female mice were intranasally instilled with two types of well-characterized <u>TiO₂ nanoparticles (i.e. 80 nm, rutile and</u>

Nano TiO₂ repeated bolus instillation into mouse: 7.5 mg into mouse = <u>17.5 grams</u> into human nose!

deposited in the hippocampus region. After exposure for 30 days, the pathological changes were observed in the hippocampus and olfactory bulb using Nissl staining and transmission electron microscope. The oxidative damage expressed as lipid peroxidation increased significantly, in particular in the exposed group of anatase TiO₂ particles at 30 days postexposure. Exposure to anatase TiO₂ particles also produced



DPPC/Alb-Dispersed MITSUI Multiwalled Carbon Nanotubes (MWCNTs)



Bolus Dosing of MWCNT: Granulomat. Inflam. and Mesothelioma = Asbestos like?

Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube

Takagi et al., J. Toxicol. Sci. 33 (No. 1): 105-116, 2008

Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study

Poland et al., Nature Nanotechnology 3, 423-428, 2008

Induction of mesothelioma by a single intrascrotal administration of multi-wall carbon nanotube in intact male Fischer 344 rats

Sakamoto et al, J.Tox. Sci., 34, 65-76, 2009

Dose-dependent mesothelioma induction by intraperitoneal administration of multiwall carbon nanotubes in p53 heterozygous mice

Takagi et al, Cancer Sci., 103(8), 1440-1444, 2012

Length-dependent pleural inflammation and parietal pleural responses after deposition of carbon nanotubes in the pulmonary airspaces of mice *Murphy et al, Nanotoxicology 7(6), 2013*

Physico-chemical NP Properties Affecting Hazard Potential

Size (*aerodynamic*, *hydrodynamic*)

Size distribution

Shape

Agglomeration/aggregation

Density (material, bulk)

Surface properties:

- area (porosity)
- charge
- reactivity
- chemistry (coatings, contaminants)
- defects

Solubility/Sol-Rate (lipid, aqueous, in vivo)

Crystallinity

Biol. contaminants (e.g. endotoxin)

Properties can change

-with: method of production preparation process storage (*aging*)

-when introduced into physiol. media, organism

-throughout life-cycle (from cradle to grave)

Physico-chemical NP Properties Affecting Hazard Potential

Size (*aerodynamic*, *hydrodynamic*)

Size distribution

Shape

Agglomeration/aggregation

Density (material, bulk)

Surface properties:

- area (porosity)
- charge
- reactivity
- chemistry (coatings, contaminants)
- defects

Solubility/Sol-Rate (lipid, aqueous, in vivo)

Crystallinity

Biol. contaminants (e.g. endotoxin)

Properties can change

-with: method of production preparation process storage (*aging*)


-when introduced into physiol. media, organism

-throughout life-cycle (from cradle to grave)


Key parameter: Dose! Expression of Dose?


Sayes et al., 2007: ASSESSING TOXICITY OF FINE AND NANOPARTICLES (In vitro and In vivo)

Crystalline Silica; Amorphous Silica; Nano Zinc Oxide; Fine Zinc Oxide




<u>Conclusion:</u> comparison of in vivo and in vitro results demonstrated little correlation






Dose-Response Analysis: Steepest slope (max response/dose) as indicator of toxicity



Rushton et al. 2010

In Vivo/In Vitro Correlation, Highest Responses Per NP Surface Area (Sayes et al, 2007)



Physical Dose-Metrics for NPs that Correlate with Biol./Toxicol. Effects (*Mode of Action*):



Surface Area

(as surrogate for surface props.)


Volume

correlation between these should be part of NP characterization

Particle Volume

Morrow Hypothesis (1988):

Lung particle overload associated impairment of alveolar macrophage clearance function correlates with phagocytized particle volume.




Relative phagocytized particle volume (% of AM volume)

Particle Volume

Morrow Hypothesis (1988):

Lung particle overload associated impairment of alveolar macrophage clearance function correlates with phagocytized particle volume.

<u>But:</u> Only for Poorly Soluble Particles of low cytotoxicity (PSP)



Relative phagocytized particle volume (% of AM volume)

Lung Particle Overload, Nanoparticles and AM mediated Particle Clearance: Does volumetric overload concept apply to nanoparticles?

12-Week Inhalation Exposure, Ultrafine and Fine TiO₂ and Cristobalite (SiO₂)

Retained dose/10⁶ AM at end of exposure							
	Mass		Volume	<u>Surface</u>	<u>Number</u>	Test Particle Retention	
	μg	nl	% of AM volume	cm^2	x 10 ⁻⁹	control = 1	
Control	0	0	0	0	0	1	
TiO₂ fine (250 nm)	340	90	9	21.9	10.9	1.8*	
(25 nm)	99.8	26	2.6	49.9	5420	8.2*	
Cristobalite	~20	7.6	0.76	2.4		28.8 *	

*Significantly different from control

Lung Particle Overload, Nanoparticles and AM mediated Particle Clearance: *Does volumetric overload concept apply to nanoparticles?*


12-Week Inhalation Exposure, Ultrafine and Fine TiO₂ and Cristobalite (SiO₂)

Retained dose/10⁶ AM at end of exposure							
	Mass		Volume	<u>Surface</u>	<u>Number</u>	Test Particle Retention	
	μg	nl	% of AM volume	cm ²	x 10 ⁻⁹	control = 1	
Control	0	0	0	0	0	1	
TiO₂ fine (250 nm)	340	90 (578)	9 (58)	21.9	10.9	1.8*	
TiO₂ ultrafine (25 nm)	99.8	26 (768)	2.6 (77)	49.9	5420	8.2*	
Cristobalite	~20	7.6	0.76	2.4		28.8 *	
		(24)	(2.4)				

*Significantly different from control (packing density volume)

Oberdörster et al, 1994

Correlation between surface area of TiO₂ particles phagocytized by AM and pulmonary retention half-time of inhaled polystyrene test particles




From: Oberdörster et al., 1994 (EHP)

Surface Reactivity as Dose-Metric, *e.g.*, ROS inducing potential to determine response per unit particle surface area


DCFH-DA (2'-7' dichlorofluorescin-diacetate) assay FRAS (ferric reducing ability of serum) assay Vit C assay others...

as screening tool for categorization of NPs based on reactivity in using cell-free assay, but only for **Hazard Identification** [Bello et al., 2009; Rushton et al., 2010]


Cell-free ROS (DCFH oxidation) Response vs In Vivo Rat PMN (Intratracheal Instill) Response to Nanoparticles Normalized to Particle Surface Area




Cell-free ROS (DCFH oxidation) Response vs In Vivo Rat PMN (Intratracheal Instill) Response to Nanoparticles Normalized to Particle Surface Area




Risk = f (hazard; exposure)




Risk = f (hazard; exposure)




Risk = f (hazard; exposure)



Approach for Comparative Hazard and Risk Characterization of Inhaled Nano-Particles Based on Subchronic (3 months) Rat Inhalation Studies



Approach for Comparative Hazard and Risk Characterization of Inhaled Nano-Particles Based on Subchronic (3 months) Rat Inhalation Studies



Case Study

90-Day Rat Inhalation Studies with MWCNT and CNF, Exposure-Dose-Response Comparison

<u>Material</u>	<u>Ma-Hock et al. (2009)</u> MWCNT (Nanocyl NC7000)	<u>Pauluhn (2010)</u> MWCNT (Baytubes)	<u>Kasai et al. (2014)</u> MWCNT (MWNT-7)	DeLorme et al. (2012) CNF (VGCF-H)
<u>Characterization</u> Length/diameter, nm Impurities BET surf area, m ² /g Packing dens, g/cm ³	100-10,000 /5-15 9.6% Al; <0.2% Co 250 – 300 0.043	200-1000/10 ~0.5% Co 255 0.11 - 0.31	2000-5700/40-90 0.2 - 0.4% 24-28 0.007	1000-14000/40 -350 0.003% Fe 13.8 0.077
<u>Exposure</u> Conctr, mg/m ³ Ret. Lung Burden	0; 0.1; 0.5; 2.5 <i>(NO)</i> No	0, 0.1; 0.4; 1.5; 6 <i>(NO</i> Yes		0.54; 2.5; 25 (<i>NO</i>) No
<u>Response</u> Lung weight (90 days) BAL–PMN (90 days)	+ 1%; + 23%; + 81% Not reported	+0; + 12; +27; +61% ~0.5; 3.8; 13; 19%	+5; +17; +30% 0.6; 13.5; 45.7%	-2; +8; +22 1.4; 2.7; 11%
<u>Evaluation</u> NOAEL LOAEL	No 100 μg/m ³	100 µg/m ³ 400 µg/m ³	No 200 μg/m ³	540 μg/m ³ 2500 μg/m ³


Case Study

90-Day Rat Inhalation Studies with MWCNT and CNF, Exposure-Dose-Response Comparison


Material	<u>Ma-Hock et al. (2009)</u>	Pauluhn (2010)	<u>Kasai et al. (2014)</u>	<u>DeLorme et al. (2012)</u>
	MWCNT (Nanocyl NC7000)	MWCNT (Baytubes)	MWCNT (MWNT-7)	CNF (VGCF-H)
<u>Characterization</u> Length/diameter, nm Impurities	100-10,000 /5-15 9.6% Al; <0.2% Co	200-1000/10 ~0.5% Co	2000-5700/40-90 0.2 - 0.4%	1000-14000/40 -350 0.003% Fe
BET surf area, m ² /g	250 – 300	255	24-28	13.8
Packing dens, g/cm ³	0.043	0.11 - 0.31	0.007	0.077
<u>Exposure</u>	0; 0.1; 0.5; 2.5 <i>(NO)</i>	0, 0.1; 0.4; 1.5; 6 <i>(NO</i>	0; 0.2; 1; 5 <i>(WB)</i>	0.54; 2.5; 25 <i>(NO)</i>
Conctr, mg/m ³ Ret. Lung Burden <u>Response</u>	No	Yes	Yes	No
Lung weight (90 days)	+ 1%; + 23%; + 81%	+0; + 12; +27; +61%	+5; +17; +30%	-2; +8; +22
BAL–PMN (90 days)	Not reported	~0.5; 3.8; 13; 19%	0.6; 13.5; 45.7%	1.4; 2.7; 11%
<u>Evaluation</u> NOAEL LOAEL	No 100 μg/m ³	100 μg/m ³ 400 μg/m ³	No 200 μg/m ³	540 μg/m ³ 2500 μg/m ³

Comparing MWCNT and CNF results with

subchronic rat inhalation studies of two Benchmark compounds:



Exposure-Response Relationships 3-Month Inhalation Studies in Rats with MWCNT, CNF, CB and Ni₃S₂ —Endpoints: Lung lavage neutrophils and lung weight —




• - MWCNT (*Pauluhn, 2010*); • - MWCNT (*Ma-Hock et al., 2009*);

- Ni₃S₂ (Oberdörster et al., unpublished);
- CNF (DeLorme et al., 2012);
- CB (Elder et al., 2005);
- MWCNT (Kasai et al., 2014)

Dose-Response relationships

3-month inhalation studies in rats with MWCNT, CNF, CB and Ni₃S₂

- Lung weight dose-responses based on retained lung burden expressed as mass, surface area and volume -



Hazard Ranking of Different (Nano)-Materials Based on Different Metrics and Steepest Slope of Exposure-Dose-Response Relationships from Subchronic Rat Inhalation Studies (endpoint: lungweight increase)

<u>Metric</u>	Ranking
Exposure Conc.:	$CNF = CB < MWCNT-K = MWCNT-P = MWCNT-MH < Ni_3S_2$
Retained Lung Bu	rden:
Mass:	$CNF = CB < MWCNT-P = MWCNT-K = MWCNT-MH < Ni_3S_2$
Surface area:	$CB < CNF = MWCNT-P = MWCNT-MH < MWCNT-K < Ni_3S_2$


Volume (bulk dens): $CB < CNF = MWCNT-K < MWCNT-MH = MWCNT-P < Ni_3S_2$

Hazard Ranking of MWCNT and CNF against Benchmark Materials based on retained Particle Surface Area and Steepest Slope of Dose-Response Relationships from Subchronic Rat Inhalation Studies (endpoint: lungweight increase)


Three Hazard Groupings:

Low: $CB \longrightarrow < 0.3 \%$ lungwt. incr./cm²Medium:MWCNT; CNF $\longrightarrow 0.3 - 1.5 \%$ lungwt. incr./cm²High:Ni₃S₂ $\longrightarrow > 1.5\%$ lungwt. incr./cm²

Estimation of Chronic NOAEL from Subchronic Rodent Study using MPPD Model



From: Oberdörster, 2002



Assumption: If retained dose is the same in rats and humans, then effects will be the same

Estimation of HEC through BMD analysis of subchronic rat studies by using rat responses as 1 St. Dev. or as 10 % above control (BMCL). Endpoint: LUNG WEIGHT Increase


<u>Material</u>	<u>Rat</u> subchronic chro <u>nic</u>					<u>Human</u> chronic			
	BMDL µg/lung	BMCL µg/m ³	Daily Depos.Dose µg/6 hr (depos.fract)		BMCL µg/m ³	BMDL µg/lung	BMDL μg/alv. compt.	Daily Depos.dose µg/8 hr (depos.fract)	<u>HEC</u> μg/m ³
MWCNT(P)	16.8	260	0.39 (0.022)	0.23	136	14,000	8,820	36.2 (0.073)	50
MWCNT(M)	4.6	72	0.11 (0.019)	0.06	41	3,830	2,413	9.91 (0.062)	16.3
CNF	97	1450	2.5 (0.022)	1.5	865	8,083	5,092	20.9 (0.064)	33.2
СВ	555	4180	13.0 (0.024)	7.7	4160	462,500	291,375	1,196 (0.076)	1600
Ni ₃ S ₂	2.98	25	0.07 (0.034)	0.04	15.3	2,483	1,564	6.42 (0.109)	6.0


MWCNT and CNF cannot be categorized as PSP

Human breathing conditions: light exercise; TV: 1024 ml; BrFreq: 20 min⁻¹; 8 hr; oro-nasal breathing

CURRENT INTELLIGENCE BULLETIN 63

2011 Occupational Exposure to Titanium Dioxide





DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health



REL: Fine: 2.5 mg/m³ Nano: 300 μg/m³



2013

<u>CHALLENGES FOR ESTABLISHING Occupational Exposure Levels (OEL)</u> <u>FOR CNT/CNF</u>:

Workplace monitoring: 1 µg/m³; distinguishable from background?


One generic OEL for all: Are all CNTs and CNFs toxicologically of equal potency?

In addition to dimension, surface modification or functionalization, tangles, straightness, level of impurities, surface defects are known to alter toxicity: $MWCNT-x \neq MWCNT-y$

However, with no convincing data to the contrary, it is prudent to treat airborne CNTs/CNFs as hazardous

<u>Needed</u>: Results of chronic rodent inhalation study

Risk Assessment and Risk Management Paradigm For Engineered Nanoparticles (NPs)



Desirable as basis for testing and for regulatory hazard and risk characterization:

Establishing toxicologically well defined Benchmark Materials as tool for classification